Research Article

Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

Arnoud J. Templeton1, Olga Ace1, Maireád G. McNamara1, Mustafa Al-Mubarak1, Francisco E. Vera-Badillo1, Thomas Hermanns2, Bostjan Seruga3, Alberto Ocaná4, Ian F. Tannock1, and Eitan Amir1

Abstract

Background: Inflammation influences cancer development and progression. An elevated platelet to lymphocyte ratio (PLR), a marker of inflammation, has been linked to poor prognosis in several malignancies. Here, we quantify the prognostic impact of this biomarker.

Methods: A systematic review of databases was conducted to identify publications exploring the association of blood PLR and overall survival (OS) in solid tumors. Data were pooled in a meta-analysis. Pooled HRs for OS by disease group and by PLR cutoff groups were computed and weighted using generic inverse-variance and random-effect modeling.

Results: Twenty studies comprising 12,754 patients were assessed. Cutoffs for PLR defining risk groups ranged from 150 to 300 and were dichotomous (12 studies; group 1) or split into three groups (<150/150–300/>300; 8 studies; group 2). Higher PLR was associated with significantly worse OS in group 1 [HR = 1.87; 95% confidence interval (CI), 1.49–2.34; P < 0.001] and with a nonsignificant association in group 2 (HR per higher category = 1.21; 95% CI, 0.97–1.50; P = 0.10). The size of effect of PLR on OS was greater for metastatic disease (HR[group 1] = 2.0; 95% CI, 1.6–2.7; HR[group 2] = 1.6; 95% CI, 1.1–2.4) than for early-stage disease (HR[1] = 1.5; 95% CI, 1.0–2.2; HR[2] = 1.0; 95% CI, 0.8–1.3). A significant association was observed for colorectal, hepatocellular, gastroesophageal, ovarian, and pancreatic carcinoma in group 1 and for colorectal cancers in group 2.

Conclusion: A high PLR is associated with worse OS in various solid tumors. Further research of its regulation and relevance in daily practice is warranted.

Impact: PLR is a readily available and inexpensive biomarker with independent prognostic value in solid tumors. Cancer Epidemiol Biomarkers Prev; 23(7); 1204–12. © 2014 AACR.

Introduction

Inflammation is a hallmark of cancer (1) and there is often a complex host–tumor relationship with most tumors having inflammatory cells and mediators present in their microenvironment (2, 3). A variety of oncogenes, tumor-secreted factors, and cytokines secreted by inflammatory cells can lead to the recruitment of inflammatory mediators (3). On the basis of these findings, a variety of markers of inflammation have been investigated for association with cancer progression and prognosis (4).

Authors’ Affiliations: 1Division of Medical Oncology and Hematology, Department of Medicine; 2Department of Surgery, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada; 3Department of Medical Oncology, Institute of Oncology Ljubljana, Slovenia; and 4Translational Oncology Unit, University Hospital, Albacete, Spain

Note: Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (http://cebp.aacrjournals.org/).

Corresponding Author: Eitan Amir, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON M5G 2M9, Canada. Phone: 416-946-4501, ext. 5181; Fax: 416-946-4563; E-mail: eitan.amir@uhn.ca
doi: 10.1158/1055-9965.EPI-14-0146
©2014 American Association for Cancer Research.

White cell and neutrophil counts, elevated C-reactive protein (CRP), and hypoalbuminemia are the biochemical parameters associated with a systemic inflammatory response that are evaluated most often (4). Several of these parameters have been converted to ratios or prognostic scores such as the Glasgow Prognostic Score (GPS, incorporating CRP and albumin; ref. 5) or the neutrophil to lymphocyte ratio (NLR; ref. 6). Platelets are also part of the inflammatory response and thrombocytosis is common in patients with solid tumors (7, 8). Platelets are known to interact with tumor cells directly and to contain factors that contribute to tumor growth, invasion, and angiogenesis (9). Platelets can protect tumor cells from natural killer cell-mediated lysis, thereby facilitating metastasis (10). The link between thrombocytosis, poor prognosis, and shorter survival time has been established in several types of solid tumors including breast, lung, colon, gastric, and ovarian cancer (11). This is thought to occur due to thrombopoietic cytokines such as interleukin-6 (IL6) being secreted by tumor cells (11). With the recognition that low lymphocyte counts may also be associated with shorter survival (12), the platelet to lymphocyte ratio (PLR) has been studied as a prognostic biomarker. It has been hypothesized that an increased PLR is indicative
of an increased host inflammatory response associated with more aggressive tumor characteristics (13).

The aim of the present study was to review the literature investigating the association of peripheral blood PLR in solid tumors with overall survival (OS) and to combine the results in a meta-analysis. Our hypothesis was that high PLR correlates with worse OS and may thus serve as a readily available and inexpensive prognostic marker in both clinical practice and for the stratification of patients in clinical trials.

Materials and Methods
This analysis was conducted in line with guidelines for the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (14).

Data sources and searches
An electronic search of the following databases was undertaken: Medline (host: OVID) from 1946 to June 2013, EMBASE (host: OVID) from 1974 to June 2013, Cochrane Database of Systematic Reviews from 2005 to June 2013. Manual searches were undertaken for abstracts presented at meetings of the American Society of Clinical Oncology from 2011 to 2013, and the European Society of Medical Oncology from 2011 and 2012 (it was assumed that abstracts presented earlier would be captured as fully published papers). Search terms included cancer, platelets, lymphocytes, and ratio. Citation lists of retrieved articles were screened to ensure sensitivity of the search strategy. The full search strategies are described in Supplementary Materials, available online.

Study selection
Inclusion criteria were: (i) studies in solid tumors reporting the prognostic impact of the peripheral blood PLR, (ii) assessment of PLR by cutoff into different risk strata, and (iii) availability of a HR for OS or Kaplan–Meier survival curves from which it could be calculated. Duplicate publications were excluded and for the main analysis so were studies that reported PLR as a continuous variable. Two reviewers (A.J. Templeton and M.G. McNamara) evaluated independently all the titles identified by the search strategy. Inter-reviewer agreement was assessed using Cohen’s kappa. Disagreement was resolved by consensus. The results were then pooled and all potentially relevant publications were retrieved in full and assessed for eligibility. Corresponding authors were contacted to clarify any missing or ambiguous data.

Endpoints of interest
Survival based on high versus low PLR was the primary outcome of interest. In exploratory analyses, we compared the relative prognostic impact of PLR with other markers of inflammation, namely the NLR, CRP, and the GPS or modified Glasgow Prognostic Score (mGPS).

Data extraction
Data were collected using predesigned abstraction forms. The following details were extracted: name of first author, type of publication (abstract or full text), year of publication, journal, number of patients included in study, disease site, disease stage [nonmetastatic, metastatic, or mixed (i.e. nonmetastatic and metastatic)], collection of data (prospective or retrospective), cutoff used to define high peripheral blood PLR, ROC curves considered for selection of cutoff (yes or no), and HR for OS with associated 95% confidence intervals (CI) or P value. If information about OS was not available, data for cancer-specific survival (CSS) was captured with the assumption that most deaths would be disease related. HRs were extracted from multivariable analyses where available. Otherwise, HRs from univariable analyses were extracted or estimated from Kaplan–Meier survival curves as described by Parmar and colleagues (15). Whenever available, HRs for survival associated with NLR, CRP, and GPS/mGPS were also collected. To evaluate the relative prognostic impact of PLR with these other markers of inflammation, HRs for subgroups defined by different markers were compared.

Data synthesis and statistical analyses
Study quality was assessed on the basis of control for confounding factors. Specifically, good quality studies were defined as those, which explicitly reported that patients with baseline infectious or inflammatory conditions were excluded form the analysis and where assessment of PLR was undertaken before treatment (surgery, systemic therapy, or radiation). Extracted data were combined into a meta-analysis using RevMan 5.2 analysis software (Cochrane Collaboration). Estimates of HRs were weighted and pooled using the generic inverse variance and random-effect model. Analyses were conducted separately for studies using two groups and for studies using three groups to define high versus low PLR. Subgroup analyses were also conducted on the basis of disease site and disease stage. Statistical heterogeneity was assessed using Cochran’s Q and I² statistics. Differences between the reported HR for subgroups defined by different inflammatory markers reported in individual studies were also assessed. Sensitivity analyses were performed using methods described by Deeks and colleagues (16). Publication bias was assessed with visual inspection of funnel plots. Meta-regression analysis was performed to evaluate the effect of study quality on the HR for OS. All statistical tests were two sided, and statistical significance was defined as P < 0.05. No correction was made for multiple testing.

Results
Included studies
A total of 22 studies were identified (Fig. 1). Cohen’s kappa for inter-reviewer agreement for paper selection was 0.78 (95% CI, 0.63–0.88). Studies included a total of 12,890 patients and characteristics of the studies are...
shown in Table 1. Most studies (59%) were published in 2012 or later. Of the 22 identified studies, 19 reported HR for OS and three for CSS. Two studies analyzed PLR as a continuous variable, twelve studies used a dichotomous cutoff for PLR (group 1), and eight defined three risk categories (group 2). All studies utilizing three risk categories reported a single HR, reflecting the average effect of comparing intermediate versus low and high versus intermediate risk (i.e., an increase of one risk category). After exclusion of the two studies analyzing PLR as a continuous variable (pooled HR for OS 1.01; 95% CI, 1.00–1.01; P < 0.001), the main analysis was conducted using data from 20 studies comprising 12,754 patients. Inspection of the funnel plots did not reveal any evidence of publication bias (Supplementary Fig. S1, available online).

Overall survival

Overall, higher PLR was associated with worse survival. Among studies of group 1 (median cutoff for PLR = 185), the pooled HR for survival for PLR above the cutoff was 1.87 (95% CI, 1.49–2.34; P < 0.001; Fig. 2A). For studies of group 2 (i.e., two cutoffs defining low, intermediate, and high PLR, usually <150, 150–300, >300), HR for OS per risk category was 1.21 (95% CI, 0.97–1.50; P = 0.10; Fig. 2B). There was statistically significant heterogeneity in both groups (group 1: Cochran Q, P < 0.001, I² = 65%; group 2: Cochran Q, P < 0.001, I² = 75%). In group 1, heterogeneity was introduced by one outlying study with HR = 4.81 (17); exclusion of this study reduced I² to 11% (P = 0.34) and changed the pooled estimate to 1.70 (95% CI, 1.47–1.95; P < 0.001). For group 2, no individual study could explain heterogeneity.
Table 1. Characteristics of included studies

<table>
<thead>
<tr>
<th>Reference</th>
<th>Disease</th>
<th>Stage</th>
<th>PLR collected pretreatment</th>
<th>Patients with infection and/or inflammatory conditions excluded</th>
<th>N</th>
<th>Cutoff</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aliustaoglu et al. (29)</td>
<td>Gastric</td>
<td>Nonmetastatic</td>
<td>Yes</td>
<td>Yes</td>
<td>168</td>
<td>160</td>
<td>OS</td>
</tr>
<tr>
<td>Asher et al. (30)</td>
<td>Ovarian</td>
<td>Nonmetastatic and metastatic</td>
<td>Yes</td>
<td>Yes</td>
<td>235</td>
<td>300</td>
<td>OS</td>
</tr>
<tr>
<td>Azab et al. (18)</td>
<td>Breast</td>
<td>Nonmetastatic and metastatic</td>
<td>Yes</td>
<td>Yes</td>
<td>437</td>
<td>185&lt;sup&gt;a&lt;/sup&gt;</td>
<td>OS</td>
</tr>
<tr>
<td>Bhatti et al. (31)</td>
<td>Pancreatic</td>
<td>Nonmetastatic</td>
<td>Yes</td>
<td>Yes</td>
<td>84</td>
<td>&lt;100/100–200/&gt;200</td>
<td>OS</td>
</tr>
<tr>
<td>Carruthers et al. (32)</td>
<td>Rectal</td>
<td>Nonmetastatic</td>
<td>Yes</td>
<td>nr</td>
<td>115</td>
<td>160</td>
<td>OS</td>
</tr>
<tr>
<td>Cordiner et al. (33)</td>
<td>Breast</td>
<td>Nonmetastatic</td>
<td>nr</td>
<td>nr</td>
<td>707</td>
<td>nr&lt;sup&gt;b&lt;/sup&gt;</td>
<td>CSS</td>
</tr>
<tr>
<td>Dutta et al. (34)</td>
<td>Esophageal</td>
<td>Nonmetastatic</td>
<td>Yes</td>
<td>Yes</td>
<td>112</td>
<td>&lt;150/150–300/&gt;300</td>
<td>CSS</td>
</tr>
<tr>
<td>Dutta et al. (35)</td>
<td>Gastric</td>
<td>Nonmetastatic</td>
<td>Yes</td>
<td>Yes</td>
<td>120</td>
<td>&lt;150/150–300/&gt;300</td>
<td>CSS</td>
</tr>
<tr>
<td>Fox et al. (36)</td>
<td>Renal</td>
<td>Nonmetastatic and metastatic</td>
<td>Yes</td>
<td>nr</td>
<td>362</td>
<td>195</td>
<td>OS</td>
</tr>
<tr>
<td>He et al. (37)</td>
<td>Colorectal</td>
<td>Metastatic</td>
<td>Yes</td>
<td>Yes</td>
<td>243</td>
<td>150&lt;sup&gt;c&lt;/sup&gt;</td>
<td>OS</td>
</tr>
<tr>
<td>Kinoshita et al. (17)</td>
<td>Hepatocellular</td>
<td>Nonmetastatic and metastatic</td>
<td>Yes</td>
<td>Yes</td>
<td>150</td>
<td>150</td>
<td>OS</td>
</tr>
<tr>
<td>Kwon et al. (13)</td>
<td>Colorectal</td>
<td>Nonmetastatic and metastatic</td>
<td>Yes</td>
<td>Yes</td>
<td>200</td>
<td>&lt;150/150–300/&gt;300</td>
<td>OS</td>
</tr>
<tr>
<td>Lee et al. (38)</td>
<td>Colorectal</td>
<td>Metastatic</td>
<td>Yes</td>
<td>nr</td>
<td>60</td>
<td>&lt;150/150–300/&gt;300</td>
<td>OS</td>
</tr>
<tr>
<td>Pinato et al. (39)</td>
<td>Hepatocellular</td>
<td>Non-metastatic and Metastatic</td>
<td>Yes&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Yes</td>
<td>112</td>
<td>300</td>
<td>OS</td>
</tr>
<tr>
<td>Pinatoet al. (40)</td>
<td>Mesothelioma</td>
<td>Nonmetastatic and metastatic</td>
<td>Yes&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Yes</td>
<td>171</td>
<td>300</td>
<td>OS</td>
</tr>
<tr>
<td>Proctor et al. (41)</td>
<td>Various</td>
<td>Nonmetastatic</td>
<td>No&lt;sup&gt;e&lt;/sup&gt;</td>
<td>No</td>
<td>8,759</td>
<td>&lt;150/150–300/&gt;300</td>
<td>OS</td>
</tr>
<tr>
<td>Raungkaewmanee et al. (42)</td>
<td>Ovarian</td>
<td>Nonmetastatic and metastatic</td>
<td>Yes</td>
<td>Yes</td>
<td>166</td>
<td>200</td>
<td>OS</td>
</tr>
<tr>
<td>Sakka et al. (43)</td>
<td>Pancreatic/periampullary neuroendocrine</td>
<td>Nonmetastatic</td>
<td>Yes</td>
<td>nr</td>
<td>32</td>
<td>Continuous</td>
<td>OS</td>
</tr>
<tr>
<td>Smith et al. (44)</td>
<td>Ampullary</td>
<td>Nonmetastatic</td>
<td>Yes</td>
<td>nr</td>
<td>52</td>
<td>160</td>
<td>OS</td>
</tr>
<tr>
<td>Smith et al. (45)</td>
<td>Pancreatic</td>
<td>Nonmetastatic</td>
<td>Yes</td>
<td>nr</td>
<td>104</td>
<td>Continuous</td>
<td>OS</td>
</tr>
<tr>
<td>Wang et al. (46)</td>
<td>Gastric</td>
<td>Nonmetastatic</td>
<td>Yes</td>
<td>nr</td>
<td>324</td>
<td>&lt;150/150–300/&gt;300</td>
<td>OS</td>
</tr>
<tr>
<td>Wang et al. (47)</td>
<td>Pancreatic</td>
<td>Nonmetastatic and metastatic</td>
<td>Yes</td>
<td>Yes</td>
<td>177</td>
<td>&lt;150/150–300/&gt;300</td>
<td>OS</td>
</tr>
</tbody>
</table>

Abbreviation: nr, not reported.

<sup>a</sup>Fourth quartile versus others.

<sup>b</sup>Considered dichotomous.

<sup>c</sup>150 versus 150–300.

<sup>d</sup>D.J. Pinato; personal communication.

<sup>e</sup>Within 2 years following diagnosis of cancer.
High PLR was associated with significantly worse survival for colorectal, gastroesophageal, hepatocellular, pancreatic, and ovarian cancers in group 1 (HRs = 1.57, 1.84, 3.33, 2.43, 1.57, respectively) but not for breast cancer (Fig. 3A). For group 2, PLR was associated with worse survival only for colorectal cancer (HR = 2.02) but not for other disease sites (Fig. 3B).

Overall, a prognostic role of PLR was observed for metastatic or mixed groups of patients (HR 2.03; 95% CI, 1.55–2.65; \( P = 0.001 \) and HR = 1.61; 95% CI, 1.10–2.37; \( P = 0.01 \) for group 1 and group 2, respectively) but only for patients with nonmetastatic disease when a dichotomous cutoff was used (HR = 1.48; 95% CI, 1.01–2.17; \( P = 0.04 \) and HR = 1.04; 95% CI, 0.82–1.32; \( P = 0.73 \) for group 1 and group 2, respectively).

In sensitivity analyses, higher values of HR were reported in full papers as compared with abstracts in group 1, but not in group 2. Further subgroup comparisons and sensitivity analyses are shown in Table 2. The scatter plot for the meta-regression is shown in Supplementary Fig. S2, available online. Overall, studies with good quality reported higher HR for OS than those for poor quality studies. This effect was observed both for studies reporting dichotomous risk groups (\( \beta = 0.537, P < 0.001 \)) and for those reporting three risk groups (\( \beta = 0.147, P = 0.001 \)).

**Comparison with other inflammatory markers**

The pooled HRs for PLR compared with other markers of inflammation, namely NLR, CRP, and GPS/mGPS were not statistically different (Table 3). Only two studies reported HRs for NLR and PLR from multivariable analyses. In one of these studies (18), both NLR and PLR retained statistical significance. In the second study, NLR was not independently prognostic after adjustment for PLR.

**Discussion**

Several studies have considered the relationship between inflammatory markers and outcome of patients with solid tumors. Here, we used meta-analysis to combine twenty studies exploring the prognostic role of PLR in 12,754 patients with solid tumors. Most of these studies have been published since 2012, highlighting the recent interest in PLR as a potential prognostic marker. We found an association between elevated PLR and poor survival. In studies reporting a dichotomous cutoff for PLR, this association was seen among several disease sites and both...
for metastatic and nonmetastatic disease, whereas it was less apparent for studies reporting three risk categories defined by two different cutoffs for PLR. Presumably, this at least in part is due to numerically lower HRs that apply per higher risk category compared with use of single cutoffs. As the direction of effect is the same, it may be hypothesized that if binary cutoffs had been used in studies reporting three risk groups, these may have

---

**Figure 3.** Prognostic impact of PLR according to disease sites. A, group 1, dichotomized cutoffs for PLR. B, group 2, two cutoffs for PLR.

---

**Table 2.** Subgroup and sensitivity analyses

<table>
<thead>
<tr>
<th></th>
<th>Group 1 (dichotomous cutoff)</th>
<th>Group 2 (three categories)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR (95% CI)</td>
<td>P&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Disease stage</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonmetastatic</td>
<td>1.48 (1.01–2.17)</td>
<td>0.04</td>
</tr>
<tr>
<td>Metastatic/mixed</td>
<td>2.03 (1.55–2.65)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td><strong>Article type</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abstract</td>
<td>0.96 (0.58–1.59)</td>
<td>0.87</td>
</tr>
<tr>
<td>Full paper</td>
<td>1.98 (1.60–2.46)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td><strong>Study type</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prospective</td>
<td>1.78 (1.49–2.14)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Retrospective</td>
<td>1.88 (1.35–2.61)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td><strong>Variable type</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multivariable</td>
<td>1.90 (1.31–2.75)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Univariable</td>
<td>1.87 (1.41–2.47)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td><strong>HR</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reported in study</td>
<td>1.67 (1.38–2.04)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Estimated from survival curves</td>
<td>2.41 (1.33–4.38)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td><strong>ROC curve</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Considered</td>
<td>2.65 (0.80–8.83)</td>
<td>0.11</td>
</tr>
<tr>
<td>Not considered</td>
<td>1.71 (1.47–1.99)</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

<sup>a</sup>P value for HR.

<sup>b</sup>P value for subgroup difference.
reached statistically significant. Sensitivity analyses of type of publication and data collection did not change the overall result.

Differences in HRs were observed between cancer sites and may be the result of inflammation playing differing roles in different types of cancer. For example, strong links with systemic inflammation and elevated inflammatory markers (CRP and GPS) have been established in colorectal cancer (4). In the present analysis, this is supported by a strong association between PLR and OS for this disease. In ovarian cancer, where we found a HR of 1.57, both thrombocytosis and elevated inflammatory markers have been linked to poor prognosis (4, 8).

The mechanisms underlying the association of high PLR and poor outcome of patients with cancer are poorly understood. Inflammatory cytokines and chemokines can be produced by both the tumor and associated host cells such as leukocytes and platelets, contributing to malignant progression (19). Indeed, we found the strongest association between PLR and survival in metastatic or mixed groups of patients when compared with study populations with locoregional disease. Although a variety of cytokines are implicated in the systemic inflammatory response, IL6 acts to increase the synthesis of acute phase proteins, including CRP, and to decrease albumin production in the liver, the two elements encompassed by the GPS (20). IL6 also stimulates the differentiation of megakaryocytes to platelets and is involved in recruitment of neutrophils (21, 22). Several studies have shown that IL6 can stimulate thrombopoietin production and can lead to increases of platelet counts in patients with cancer (23). In patients with ovarian cancer, high IL6 level is an independent predictor of poor prognosis (8). Furthermore, serum concentration of IL6 has been shown to be increased in 13 different cancer types and has been associated with tumor stage and disease progression (22).

In an exploratory analysis, we compared the relative prognostic impact of PLR with other markers of inflammation, namely NLR, CRP, and GPS/mGPS and did not find any of these to be a stronger prognostic marker than PLR. In studies reporting HRs for both NLR and PLR, NLR was associated with a numerically higher HR for death in univariable analysis; this may be due to the more varied properties of neutrophils in comparison with platelets, such as the secretion of various cytokines (24–27), but this difference did not reach statistical significance. Either CRP or GPS/mGPS might be stronger predictors of survival than PLR but data from only two studies were available for comparison. Overall, it is likely that common mechanisms lead to concurrent elevation of multiple inflammatory factors.

Limitations of this study include the fact that only summarized data rather than individual patient data could be used and that two studies were published only in abstract form and have not undergone rigorous peer review. Second, most studies (70%) provided only HRs from univariable analysis which could introduce a bias toward overestimation of the prognostic role of PLR, as HRs in multivariable analysis may have been nonsignificant due to inclusion in the multivariable model of other markers of systemic inflammation such as CRP, hypoalbuminemia, GPS, or NLR. We aimed to address such confounding by performing sensitivity analyses and did not find a significant difference between subgroups. Furthermore, studies not reporting HRs or Kaplan–Meier curves were excluded, potentially introducing further bias. Finally, we cannot exclude the possibility that nonmalignant factors may have influenced the reported PLR. Authors of most studies included in our analysis explicitly excluded patients with infection and/or inflammatory conditions and some mentioned exclusion of patients with hypothyroidism, hyperthyroidism, temperature >37.2C, or patients on glucocorticoids or nonsteroidal anti-inflammatory drugs. Furthermore, most studies reported that PLR was calculated from blood counts drawn before actual treatment. Our meta-regression suggests that the effect size of PLR on OS was greater in studies with more comprehensive exclusion of nonmalignant causes of inflammation. Therefore, it is possible that our inclusion of studies without robust control for confounders actually diluted the effect of PLR on outcome.

To establish PLR as a prognostic marker, the clinical significance of this indicator must be further validated. The cutoff value must be established in one cohort of patients and tested in another and the number of patients in each group needs to be considered in the statistical analysis (28). With the use of patient level data, the overlap of outcomes between high and low risk of PLR must be considered. The differing results by cancer site and

---

**Table 3. Comparison of relative risk of HR between PLR, CRP, and GPS (group 1 only)**

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Studies (N)</th>
<th>Pooled HR for PLR (95% CI)</th>
<th>Pooled HR for comparator (95% CI)</th>
<th>Subgroup difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLR vs. NLR (multivariable*)</td>
<td>2</td>
<td>2.13 (1.36–3.33)</td>
<td>1.76 (0.44–7.13)</td>
<td>0.800</td>
</tr>
<tr>
<td>PLR vs. NLR (univariable*)</td>
<td>7</td>
<td>1.76 (1.42–2.18)</td>
<td>2.20 (1.52–3.20)</td>
<td>0.310</td>
</tr>
<tr>
<td>PLR vs. CRP (univariable*)</td>
<td>2</td>
<td>1.66 (1.20–2.29)</td>
<td>1.96 (1.43–2.68)</td>
<td>0.470</td>
</tr>
<tr>
<td>PLR vs. GPS/mGPS (univariable*)</td>
<td>2</td>
<td>1.66 (1.20–2.29)</td>
<td>2.14 (1.55–2.95)</td>
<td>0.280</td>
</tr>
</tbody>
</table>

*HR derived from univariable and multivariable models, respectively.
metastatic compared with locoregional disease reported here suggest that prognosis based on PLR may not be generalizable across different patient groups.

In summary, this meta-analysis concludes that a high PLR is an independent factor associated with poorer OS in many solid tumors and is comparable with other established hematologic markers of inflammation. As a cost-effective and readily available biomarker, PLR may thus be useful in the clinical setting. Investigation of the addition of PLR to established prognostic scores to stratify patients in clinical trials is warranted. The selection of the most relevant marker of inflammation to indicate prognosis will require head to head comparisons.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: A.J. Templeton, M.G. McNamara, F.E. Verabaddillo, T. Herrmanns, A. Ocana, I.F. Tannock, E. Amir

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A.J. Templeton, M.G. McNamara
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A.J. Templeton, M.G. McNamara, F.E. Verabaddillo, T. Herrmanns, A. Ocana, E. Amir
Writing, review, and/or revision of the manuscript: A.J. Templeton, C. Acce, M.G. McNamara, M. Al-Mubarak, F.E. Verabaddillo, T. Herrmanns, B. Seruga, A. Ocana, I.F. Tannock, E. Amir
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A.J. Templeton, E. Amir
Study supervision: A.J. Templeton, A. Ocana, I.F. Tannock, E. Amir

Acknowledgments
The authors thank Junhui Zhang from the Princess Margaret Library for running the literature searches and Priya Aneja for her great help with checking data.

Grant Support
This work was supported by a grant from the Swiss Cancer Research Foundation (to A.J. Templeton).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received February 3, 2014; accepted April 15, 2014; published OnlineFirst May 3, 2014.

References


Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

Arnoud J. Templeton, Olga Ace, Mairéad G. McNamara, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1055-9965.EPI-14-0146

Supplementary Material
Access the most recent supplemental material at:
http://cebp.aacrjournals.org/content/suppl/2014/05/05/1055-9965.EPI-14-0146.DC1

Cited articles
This article cites 44 articles, 6 of which you can access for free at:
http://cebp.aacrjournals.org/content/23/7/1204.full.html#ref-list-1

Citing articles
This article has been cited by 7 HighWire-hosted articles. Access the articles at:
/content/23/7/1204.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.